Alternatives to amyloid for Alzheimer's disease therapies-a symposium report

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Decades of Alzheimer's disease (AD) research centered on amyloid pathology.
• Amyloid-targeting therapies have shown limited success in preventing cognitive decline.
• The lack of approved disease-modifying agents necessitates exploring alternative therapeutic strategies for AD.

Framework:

• The symposium highlighted the need for timely intervention targeting specific AD pathologies.
• Focus shifted towards understanding AD as a complex disease with multiple contributing factors.
• Exploration of novel therapeutic targets beyond amyloid is crucial for effective AD treatment.

Implementation:

• Preclinical and early clinical studies are investigating targets such as neuroinflammation, tau protein, vascular health, and the gut microbiome.
• Symposium discussions emphasized the importance of a multi-faceted approach to AD drug development.
• Presentations covered emerging research on non-amyloid targets for Alzheimer's disease therapeutics.

Implications:

• Identifying and validating alternative targets could lead to the first approved disease-modifying therapies for Alzheimer's.
• A paradigm shift in AD research towards diverse pathologies may accelerate therapeutic breakthroughs.
• Future AD treatments may involve combination therapies targeting multiple disease pathways.